Composition
Each tablet contains 500 mg pyrazinamide.
Properties
Pyrazinamide is highly effective as a bactericidal drug against tubercle bacilli. It exerts its effect in vivo in acidic loci in the body where tubercle bacilli are found, for instance, within phagocytic cells and in caseous lesions.
It is also active against bacilli resistant to other antituberculous drugs. Because of its unique activity against tubercle bacilli in an acid environment .
Pyrazinamide is now considered to be an important first-line agent in the intensive phase of short term antituberculous regimens. The product is not against atypical mycobacteria.
Pharmacokinetics
Pyrazinamide is readily absorbed from the gastrointestinal tract. Peak serum concentrations occur about 2 hours after oral administration.
The half-life has been reported to be about 9 to 10 hours. Pyrazinamide is widely distributed in body fluids and tissues and difuses into CSF.
It is metabolised primarily in the liver and about 70% of the dose appears in the urine within 24 hours mainly as metabolites and 4 to 14% as unchanged drug.
There are no major changes in the blood kinetics of pyrazinamide, isoniazid and rifampicin when the three drugs are administered separately or in a fixed combination over a 2 month period of continuous daily drug administration.
Indications
Pulmonary and extrapulmonary treatment of tuberculosis.
Contraindications
Liver damage Acute porphyria Pregnancy
Adverse Effects
Hepatic reaction, which may range from asymptomatic impaired liver function to hepatitis with or without jaundice. The hepatic reaction is reversible after stopping the drug.
Hyperuricemia due to renal inhibition of urate excretion.
Other side effects are rare and may include anorexia, nausea, vomiting, malaise, mild fever and skin rashes.
Dosage
Adults: 15-35 mg/kg body weight, up to a maximum of 3 g (6 tablets) daily, given in 3 or 4 equally divided doses.
Children: 20 mg/kg body weight per day
How Supplied
Strips of 10 tablets in packs of 2 strips.
Keep all medicaments out of reach of children
Product of: AMOUN PHARMACEUTICAL CO. El-Obour City, Cairo, Egypt. ATC Code: J04AK01
Dr. Ahmad Baker, PharmD
Senior Pharmacist & Health Educator
With over 23 years of clinical experience in hospital and community pharmacy across Egypt and Saudi Arabia, Dr. Ahmad specializes in reproductive health and pharmaceutical safety. He is dedicated to providing evidence-based guidance to empower patients in the MENA region.
Medical Disclaimer: This content is for educational purposes and reflects the latest pharmaceutical protocols. It is not a substitute for personal medical advice. Always consult Dr. Ahmad Baker or your healthcare provider before starting any treatment.